Introduction Crossignal Therapeutics is developing new generation of small molecule anti-cancer immunotherapies. They focus on the discovery of immune cell-expressed, tumor metabolic factors (TME)-targeted GPCRs (TMERs) and design drug candidates by testing their ability to inhibit critical pathways in TME-mediated cancer immune escape. |